Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

LONDON, December 12, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that the United States Patent and Trademark Office (USPTO) has completed its reexamination of four key RNAi patents that form part of the foundational "Zamore Design Rule" patent families. Following a review requested by an anonymous third party during 2010, the USPTO has concluded that the reissued claims are patentable and has issued Notices of Intent to Issue Reexamination Certificates. The prior art cited in the reexaminations was unsuccessful in invalidating the patents.

The four patents (US 7,459,547, US 7,732,593, US 7,772,203 and US 7,750,144) form part of the foundational "Zamore Design Rule" patent families that disclose various efficacy-enhancing methods and structural elements for RNAi therapeutics. Silence has exclusively licensed three "Zamore Design Rule" patent families in their entirety for applications in the human healthcare field from the University of Massachusetts Medical School. The three patent families generally disclose methods of enhancing the silencing activity of RNAi agents through certain structural modifications. The claims associated with the reexaminations include coverage for methods of enhancing silencing of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin RNA (shRNA) molecules.

Thomas Christély, Chief Executive Officer of Silence Therapeutics, said: "We are very pleased that the USPTO has reissued these four patents. This outcome sends a clear message regarding the strength of Silence's intellectual property. We believe that there is significant value in the Zamore technology as a fundament
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/10/2014)... Toronto, Canada (PRWEB) July 10, 2014 ... often present in very low abundance and are ... quite challenging and time-consuming. , Join presenters Dr. ... Laboratories, and Dr. John Anders, Head of Quality ... mass spectrometer-based approach that can speed detection and ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... WILMINGTON, N.C., Sept. 9 Wilmington Pharmaceuticals announced ... granted marketing approval for METOZOLV((TM)) ODT (metoclopramide HCl), an ... gastroesophageal reflux disease (GERD) and diabetic gastroparesis. Wilmington has ... pharmaceutical company with a focus on gastrointestinal disorders. , ...
... , SAN DIEGO, Sept. 9 Orexigen((R) )Therapeutics, Inc. ... obesity, today announced that the Company will be speaking at two upcoming investor ... , Morgan Stanley Global Healthcare Unplugged Conference, ... Time, Location: Grand Hyatt Hotel, New York, ...
... , , , , ... SAN FRANCISCO, Sept. 9 Medivation, Inc. (Nasdaq: MDVN ) ... the following conferences: , , , The ... Eastern Time at the Millennium Broadway Hotel in New York , ...
Cached Biology Technology:Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 2Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 3Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 4Medivation Announces Participation in Upcoming Conferences 2
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... July 11, 2014--Researchers at the Department of Energy,s ... 100 awards, presented by R&D Magazine in recognition ... "These awards recognize the tremendous value of our ... "Research and development at the National Labs continues ... and pursue the scientific and technological innovations necessary ...
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... In Nature, cells and tissues assemble and organize themselves ... their structure and function, such as the elasticity of ... design principles have now been successfully replicated in the ... Inspired Engineering and the School of Engineering and Applied ...
... ANN ARBOR, Mich. Why do some diseases ... the University of Michigan have found neural tissue contains ... susceptibility to a debilitating childhood movement disorder. ... and repetitive movements or abnormal postures. It,s caused by ...
... is an imposing bull always in search of the best ... 4 metres in length belongs to a group of 14 ... scientific assistants since recently. At the beginning of the Antarctic ... the mighty elephant seal bulls were tagged with state-of-the-art satellite ...
Cached Biology News:Harvard's Wyss Institute uses nature's design principles to create specialized nanofabrics 2Harvard's Wyss Institute uses nature's design principles to create specialized nanofabrics 3Neural tissue contains imbalanced levels of proteins, U-M study finds 2Seal bulls in the service of science 2Seal bulls in the service of science 3
... foil heat sealing material is suitable ... a screw down heated lid), especially ... useful method for sample retrieval. Multiple ... existing seal. Ideal for compound management ...
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.2 micron filtration, ... This formulation insures consistently high levels of ...
... Blot Strong Antibody Stripping Solution is effective ... that have been developed with chemiluminescence or ... not recommended for stripping colorimetric substrates (TMB, ... possible to effectively remove substrates that precipitate ...
...
Biology Products: